На главнуюНовости и политикаПохожее видеоЕще от: Proactive Investors Stocktube

US deal launches OptiBiotix's LPLDL probiotic into huge pharma space

Оценок: 0 | Просмотров: 845
Per Rehne, commercial director at OptiBiotix Health PLC (LON:OPTI), tells Proactive's Andrew Scott they've licensed out their cholesterol-lowering bacteria to an unnamed US company, which plans to use it to create a high-value pharmaceutical drug. Discussing some of the numbers involved, Rehne says Opti will receive a six-figure payment on the official signing of the agreement and two ‘milestone’ awards totalling seven figures. An additional six-figure amount, plus royalties on future sales, would be due if a product was launched. Furthermore they'll receive a seven-figure payment should the American business decide to exercise its option to broaden the licence agreement out to a global deal.
Html code for embedding videos on your blog
Текстовые комментарии ()

Хотите оставить комментарий?

Присоединитесь к YouTube, или войдите, если вы уже зарегистрированы.